For how we live.
A Danish stepped-wedge trial gave endoscopists automated feedback on their technique after every procedure. Adenoma detection rose from 43.4% to 48.6% — a different tool from real-time polyp AI.
In the 172-patient PARADIGM trial, azacitidine plus venetoclax more than doubled median event-free survival versus induction chemotherapy — but it was a phase 2 study not powered for overall survival.
Stargardt disease, the most common inherited macular dystrophy, has no approved treatment. In the 50-patient TEASE-1 trial, gildeuretinol slowed atrophic lesion growth by a fraction of a millimetre a year.
In an early-phase trial of 136 previously treated patients, daraxonrasib produced responses in 31–37% depending on dose — but 54% had a serious side effect, and this is a phase 1–2 study.
In the Ket-BD trial, four IV ketamine infusions over two weeks lowered depression scores more than an active placebo, with no manic switches observed in 63 analysed patients.
In the NSABP B-59 trial, adding the immunotherapy to neoadjuvant chemotherapy did not significantly improve event-free survival, while immune-related side effects more than doubled.
Ervebo was licensed against Zaire ebolavirus. WHO says it is not known whether it protects against Bundibugyo virus in humans — which is why a trial is running alongside the wider rollout.
Lorecivivint improved pain modestly and changed nothing structural. Sprifermin grew cartilage and the effect made no difference by year five. Both illustrate the gap between a biomarker and a benefit.
A Federal Register notice opens a five-day comment window in September. The stated goal is to realign clinical operations across the institute and align with Presidential priorities.
DANISH-CRT randomised 1,000 patients to electrically targeted or conventional left ventricular lead placement. After nearly four years, death and heart failure admissions were the same.
PRAGUE-26 randomised 558 patients across 11 Czech hospitals. The seven-day composite fell from 6.8% to 0.7%, driven by cardiorespiratory collapse, with no clear bleeding penalty.
PREMIUM tested prasugrel alone against aspirin plus prasugrel in 2,216 STEMI patients in Japan. Monotherapy failed to show noninferiority, and the confidence interval sat above one.
POET II randomised 508 stabilised patients to stop antibiotics or complete the standard course. The safety endpoint met noninferiority; relapse of infection did not go the same way.
LIBREXIA-ACS enrolled 14,194 patients before stopping for futility. Milvexian did not reduce events, but intracranial and fatal bleeding were identical to placebo, which is the class's whole premise.
CARDIO-TTRansform randomised 1,432 patients with transthyretin amyloid cardiomyopathy to eplontersen or placebo for 140 weeks. The confidence interval around the primary result crosses one.
Guidelines have hedged on anticoagulation for people with one stroke risk factor. SINGLE-AF randomised 1,803 patients in South Korea, and the events it counted were very few in both arms.
A meta-analysis of 90,000 people found these diabetes-origin drugs reduced kidney disease progression by 37% and cardiovascular events by 23%, and the benefit was similar in people who did not have diabetes.
ACACIA-HCM met both primary endpoints in symptomatic non-obstructive HCM. The gains were real but small, and one in ten patients had a reversible drop in pumping function.
A network meta-analysis found route of delivery decides everything, and that autologous transplant ranked below placebo. In IBS, 13 trials produced very low certainty of any effect.
A $12 million gift will test whether low-dose rapamycin changes the transition to frailty in adults over 65 — the first study of the drug designed around an outcome rather than a biomarker.
High urate levels track with worsening kidney disease, so treating them seemed a logical way to slow it. Two trials that lowered urate with allopurinol found the kidneys declined at the same rate anyway.
The longest human trial of low-dose rapamycin for healthy ageing found no change in visceral fat, its own primary outcome. The positive findings it is quoted for rest on eight women.
The MTA trial randomised 579 children and found medication management clearly superior short-term. Its own long-term follow-up found the treatment groups no longer differed by 6 to 8 years.
Post-bariatric hypoglycemia hits roughly 1 in 12 gastric bypass patients with sudden blood sugar crashes. Avexitide cut severe events by 55% against placebo.
A ten-person phase 1 study measured whether oral rapamycin reaches the central nervous system in early Alzheimer's. It did not — and several disease biomarkers rose over eight weeks.
A 100-child randomized trial in Uganda found a cheap supplement lowered infection rates on top of standard hydroxyurea therapy — though the authors say it needs a bigger trial before it changes practice.
Adding an inhaled steroid to the as-needed inhaler roughly halved severe attacks against a short-acting reliever, at a fraction of the daily steroid exposure that maintenance therapy delivers.
VPM1002 did not show non-inferiority to BCG for preventing tuberculosis infection in a phase 3 trial across sub-Saharan Africa. Far fewer infections occurred than planned, leaving the comparison unresolved.
Observational studies link higher water intake to healthier kidneys. When a randomised trial coached people with kidney disease to drink more, their filtration fell at the same rate as the control group.
A phase 2 trial of dasatinib plus quercetin missed its bone endpoint. A senolytic injected into the eye produced a 5.6-letter vision gain whose confidence interval crosses zero.
In a trial of 1,643 men, prostate cancer killed 3.1% of the monitored group and 2.2% of the surgery group — a difference the trial could not distinguish from chance. Metastases were twice as common.
Longevity trials want a measurement that moves in months instead of decades. A Berlin study ranked the candidates, and a four-week diet trial showed what a clock does when nothing much happens.
The label follows people for life, pushes them onto second-line antibiotics, and is associated with higher rates of MRSA and C. difficile. A randomised trial tested a faster way to remove it.
Analgesic trials keep failing, and one reason is that the comparison arm keeps improving. Where a trial recruits, how long it runs and how big it is all move the placebo response — and none of that is about the drug.
The randomised evidence in older men found a moderate effect on sexual function and none on vitality or walking. A 5,246-man safety trial cleared it on heart attacks and found more fractures.
Both things are true, and both rest on high-certainty evidence. The phase 3 trial and the meta-analysis that followed it measured different outcomes and reached opposite-sounding conclusions.
The LEAP trial reversed a generation of avoidance advice. A second trial run in the general population missed its primary endpoint, and the distance between those two results is the part usually left out.
Years of observational data suggested 4CMenB cut gonorrhea risk by a third or more. A placebo-controlled trial in 654 people at high risk found essentially no effect at all.
The KADS extension followed 130 patients who had already been through a ketamine trial. Response fell from 30% at treatment's end to 17% a month later.
A sham-controlled trial found FMT shifted bacterial composition but cleared drug-resistant organisms no better than a saline placebo. A second trial shows what a defined replacement product can and cannot yet prove.
35% of patients on tezepelumab stopped oral steroids entirely, versus 21% on placebo, without losing asthma control — in a drug that targets inflammation upstream of the eosinophil count doctors usually check.
A new structured dataset finally makes the approvals countable. Two trials published weeks apart show why counting them says little: 0.86 fewer migraine days in one, a 20-point symptom shift in the other.
EPISODE randomized 144 people with treatment-resistant depression across four arms. High-dose psilocybin missed its main outcome, even as secondary measures showed symptom benefit.
A study running 5.3 million evaluations through nine large language models found eligibility judgments were largely stable across identity labels — except when a patient vignette mentioned homelessness.
In 35 patients with recurrent major depression, psilocybin beat an active placebo through day 42. On self-reported measures the effect lingered further, but the trial's primary endpoint showed no difference at 365 days.
TSND-201 improved PTSD severity, disability, and depression scores over placebo in 65 participants — delivered as an oral dose with monitoring but no formal psychotherapy alongside it.
Buntanetap showed dose-dependent cognitive benefit in biomarker-positive patients with mild disease. The company's announcement does not say what happened in the full 351-patient population.
A systematic review of 27 studies finds women reach higher drug concentrations at the same psychotropic dose. A separate review of 103 atrial fibrillation trials finds 43% under-enrolled women against disease prevalence.
Results posted to ClinicalTrials.gov show 15- and 25-day nirmatrelvir-ritonavir regimens produced no meaningful edge over placebo on cognitive, autonomic, or exercise-intolerance symptoms.
Up to eight sessions of psilocybin, layered onto a small randomized comparison against an active placebo, produced a 73% response rate by the end of treatment. The trial was designed to test safety first.
Bimagrumab targets fat, not appetite. Paired with semaglutide in 507 adults with obesity, the combination out-performed either drug alone at 48 weeks — with its own separate set of side effects.
A trial across five Chinese hospitals found remote robotic urological surgery non-inferior to local surgery. The sample is small, the surgeons were experts, and the network never failed.
In the RECOVER extension, about a fifth of participants were in remission at 24 months and some who had not responded at 12 months did later. The second year had no control group.
FDA approved copper histidinate on the strength of two single-arm trials compared with an external control group. Children treated within four weeks of birth had a 78 percent lower risk of death.
Standard questionnaires found no daytime difference between suvorexant and placebo. Four-times-daily smartphone prompts found fatigue worse in the morning and better later. The trial had 40 people.
The biomarker effect reported at CTAD is large and sustained over two years. The sample is seven, the design is open dose-escalation, and imaging was available for three.
TRIUMPH-4 tested retatrutide in 445 adults with obesity and knee osteoarthritis. The weight numbers are striking. So are the discontinuation numbers sitting beside them.
Bristol Myers Squibb found 'irregularities' in how a small number of ADEPT-2 sites executed the study, excluded their patients, and is enrolling more. Alzheimer's-related psychosis still has no approved treatment.
Semaglutide moved Alzheimer's biomarkers without moving the clinic. A separate liraglutide trial missed its primary endpoint on brain metabolism. Together they close a decade-old hypothesis — or at least narrow it.
Two November trials found ambient AI cut documentation time and work exhaustion. A parallel emergency department comparison found physicians spent more time in the note, not less.
In ATTAIN-2, the highest dose of the oral GLP-1 pill cut body weight 9.6% over 72 weeks in adults with type 2 diabetes, against 11.2% in the earlier trial of adults without diabetes.
A TB vaccine financing plan, six target product profiles for children's cancer drugs, and a paediatric research agenda. All three are attempts to specify a product before a market decides to build it.
SURPASS-CN-INS randomised 257 adults at 26 Chinese hospitals. The 10 mg and 15 mg doses performed almost identically against placebo, and diarrhoea affected roughly a third of those on the higher doses.
Seltorexant held its effect over two weeks while zolpidem's faded, in a 364-person study run in 2017-2019 and published only now. The delay is disclosed in the paper itself.